rs111770298 - BABAM2
Magnitude 2.2 · 1 study on file
Reported associations
-
Genome-wide association analysis identifies ancestry-specific genetic variation associated with acute response to metformin and glipizide in SUGAR-MGH - Unknown journal (n.d.) · Unknown authors · PubMed 37233759
ABSTRACT: Aims/hypothesis Characterisation of genetic variation that influences the response to glucose-lowering medications is instrumental to precision medicine for treatment of type 2 diabetes. The Study to Understand the Genetics of the Acute Response to Metformin and Glipizide in Humans (SUGAR-MGH) examined the acute response to metformin and glipizide in order to identify new pharmacogenetic associations for the response to common glucose-lowering medications in individuals at risk of type 2 diabetes. Methods One thousand participants at risk for type 2 diabetes from diverse ancestries underwent sequential glipizide and metformin challenges. A genome-wide association study was performed using the Illumina Multi-Ethnic Genotyping Array. Imputation was performed with the TOPMed referen
Auto-generated from study metadata. AI-synthesised commentary is added when this entry is regenerated through content-service's LLM mode.
Lifestyle context
Concrete actions anchored to the cited research. We do not prescribe, we describe.
Discuss with your doctor
-
metformin dosing and efficacy Moderate
G allele carriers at rs111770298 show reduced fasting glucose response to metformin in pharmacogenetic studies.
if prescribed metformin, discuss whether standard dosing is appropriate or alternative approaches should be considered
Lifestyle
-
intensive lifestyle modifications for diabetes prevention Moderate
Reduced metformin response makes lifestyle interventions more critical, since medication may be less effective.
prioritize regular exercise, dietary modifications, and weight management